Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017
05 janv. 2017 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)
28 déc. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
Galena Biopharma Announces the Phase 2 Clinical Trial of NeuVax™ (nelipepimut-S) in Ductal Carcinoma in Situ (DCIS) is Open for Enrollment and Screening Patients
14 déc. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium
12 déc. 2016 07h05 HE
|
Galena Biopharma, Inc.
NeuVax™ (nelipepimut-S) Phase 2 VADIS trial design in women with ductal carcinoma in situ (DCIS)GALE-301 and GALE-302 Phase 1b clinical data in breast cancer patients SAN RAMON, Calif., Dec. 12,...
Galena Biopharma to Present Two Posters at the San Antonio Breast Cancer Symposium
30 nov. 2016 13h31 HE
|
Galena Biopharma, Inc.
VADIS: Phase 2 Trial of the Nelipepimut-S Peptide Vaccine in Women with DCIS of the BreastGALE-301 and GALE-302 data in breast cancer patients SAN RAMON, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) --...
Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the Society for Immunotherapy of Cancer Conference 2016
14 nov. 2016 07h05 HE
|
Galena Biopharma, Inc.
Presentation provides immunologic and booster data on GALE-301/GALE-302 SAN RAMON, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company...
Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update
09 nov. 2016 16h10 HE
|
Galena Biopharma, Inc.
GALE-401 expected to initiate a Phase 3 clinical trial in Q2, 2017Top-Line results from NeuVax™ (nelipepimut-S) PRESENT Clinical TrialWebcast and conference call today at 2:00 p.m. P.T. / 5:00 p.m....
Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer
03 nov. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
Galena Biopharma Announces Reverse Stock Split
31 oct. 2016 16h30 HE
|
Galena Biopharma, Inc.
1-for-20 Reverse Stock Split Effective November 11, 2016 for Trading November 14, 2016 SAN RAMON, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a...
Galena Biopharma to Report Third Quarter 2016 Financial Results and Provide a Corporate Update on Wednesday, November 9, 2016
26 oct. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...